

LifeSci Biotechnology Clinical Trials Index

11/3/2021

Effective at the market close on Thursday, November 4, **KDMN will be removed from the LifeSci Biotechnology Clinical Trials Index** and its value will be redistributed to the remaining index components based on their weights.

- On September 8, 2021, Kadmon Holdings, Inc. agreed to be acquired by AstraZeneca plc for \$9.50 per share in cash.